

PATIENT ORGANISATION SUPPORT AGREEMENT

This patient organization support agreement (the "Agreement") is made effective as of 20.06.2020 (the "Effective Date"), between between Swedish Orphan Biovitrum A/S, Sorgenfrivej 17, 2800 Lyngby ("Sobi") and Danmarks Bløderforening, Kompagnistræde 22, 2. sal baghuset, 1208 København K ("Recipient").

WHEREAS, Sobi is an international biopharmaceutical company dedicated to rare diseases;

WHEREAS, Recipient is Danmarks Bløderforening; and

WHEREAS, Sobi has agreed to co-support (among other companies) the production of movies around life with bleeding disorders (the "Movie project") on the terms and conditions set out below.

NOW, THEREFORE, the parties agree as follows:

1. TERMS AND CONDITIONS OF SUPPORT

- 1.1 **Support:** Sobi hereby agrees to provide Recipient the sum of 19.531 DKK (nineteenthousandfivehundredandthirtyone Danish Kroners) + applicable VAT as a bona fide grant for the purpose of supporting a portrait movie project. The movie will present people's lives with bleeding disorders and will raise awareness and focus on life and possibilities (the "Support").
- 1.2 **Scope:** The Support shall only cover actual, documented, reasonable and direct costs that are necessary in order to carry out the professional parts of the movie project, as further specified in Schedule 1. Activities and materials generated as a result of this Support shall comply with all applicable laws and regulations.
- 1.3 **Budget and Repayment:** Recipient shall provide Sobi with a complete budget for the Movie project. Actual costs for the parts sponsored by Sobi shall be reported to Sobi no later than 20.06.2020. Unused budget resources shall be repaid to Sobi without delay after the Movie project is final or immediately if the Movie project is cancelled.
- 1.4 **Payment Terms:** Sobi shall pay Recipient by electronic bank transfer in accordance with the above agreed payment schedule. The Bank details of Recipient are as follows: Danmarks Bløderforening, Reg. number 7040 Account number 1106847.
- 1.5 **Communication:** Sobi will be transparent regarding its support and the Recipient agrees to be similarly transparent.

1.6 **Use of Sobi name:** Recipient shall only use the name and logotypes of Sobi, in publications, presentations, programmes, other printed or orally presented materials or otherwise, after prior review and approval of Sobi.

1.7 **No inducement:** Recipient acknowledges that provision of the Support is in no way an inducement to recommend, prescribe, purchase, supply, sell or administer a particular medicinal product.

2. MISCELLANEOUS PROVISIONS

2.1 **Entire Agreement:** This Agreement, including its Schedules, constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior oral or written agreements of the parties with respect to such subject matter

2.2 **Amendments:** No provision of this Agreement may be amended, modified or otherwise changed, other than by an instrument in writing duly executed on behalf of the parties to this Agreement.

2.3 **Assignments:** This Agreement is personal to the parties who shall not have any right to assign it without the prior written consent of the other party, except that Sobi shall have the right to assign the Agreement to its affiliates.

2.4 **Independent Contractors:** In making and performing this Agreement, the parties are acting and shall act at all times as independent contractors, and nothing contained in this Agreement shall be construed or implied to create any agency, partnership or employer and employee relationship between Sobi and Recipient. At no time shall any party make commitments or incur any charges or expenses for or in the name of any other party, other than as expressly set forth herein.


2.5 **Transfer of Value Disclosure Codes:** Recipient acknowledges that any transfer of value ("ToV") made by or on behalf of Sobi pursuant to this Agreement may be reported to government entities or other third parties as required by law or industry codes and that Sobi may disclose such payments on its website or as otherwise required by such laws or codes. Recipient shall assist Sobi in its compliance with applicable laws, regulations and transparency principles with respect to such transfer of value and will provide any information necessary to comply with any reporting as required by applicable law or industry code.

- 2.6 **Governing Law and Jurisdiction:** This Agreement shall be governed and construed by the substantive laws of Denmark. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by the courts of the above said country.

[Signatures to follow on the next page.]

This Agreement has been signed by each party's duly authorized signatory(ies). This Agreement may be executed and transmitted via email in Portable Document Format (PDF), and in counterparts, each of which taken together, shall constitute one agreement binding on the parties with the same force and effect as an original signed agreement.

Swedish Orphan Biovitrum A/S


Name: Mai Clifford
Title: Country Manager
Date: 16/6 - 2020

Danmarks Bløderforening

Danmarks Bløderforening

Kompagnistræde 22, 2.

1208 København K

Tlf. 33 14 55 05

CVR-nr. 11 80 29 90

Name: Karen Birger Holm

Title: Head of the Secretariat

Date: 22/6 - 2020

Name:

Title:

Date:

SCHEDULE 1**SUPPORT AND COSTS**

Sobi supports a portrait movie showing life with bleeding disorders anno 2020. Woman with Von Willebrand (diagnosed) and man 30+ with haemophilia (tendon injuries and new treatment) and small children's familie with child with bleeding disorder (how disease and treatment affects the family).

Budget

Portrætfilm*	DKR	Pr. firma
Film - småbørnsfamilie	43.750 DKR	
Film 30+/hæmofili	43.750 DKR	
Film – kvinde/vW	43.750 DKR	
Projektledelse**	25.000 DKR	
Portrætfilm, i alt	156.250 DKR	19.531 DKR

Budget is based on an offer from Velvet Production.